Based in Zug (Switzerland), Lallemand Pharma International (LPI) is a pharmaceutical subsidiary of the Lallemand group. LPI is in charge of the business and possesses the intellectual property rights of an oral vaccine indicated in the prevention of respiratory infections known as PMBL™ .
Lallemand Pharma AG, subsidiary of LPI, based in Lugano (Switzerland) is dedicated exclusively to the clinical studies, registrations, marketing and sales of this PMBL™ drug.
Thanks to its important distributor’s network consisting of leading international pharmaceutical companies, the core business of Lallemand Pharma is to develop and market all around the world drugs containing PMBL™ tablets under different brands.
Lallemand Pharma AG works in a B to B model and provides with key turn PMBL™ tablets to leading International Pharmaceutical companies.
Our PMBL™ tablets, made of bacterial lysates obtained by unique mechanical lysis process, are distributed worldwide:
Registrations are on-going in ROW countries.
To obtain more information you can connect at: www.lallemandpharma.com